Difference between revisions of "Vandetanib (Caprelsa)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Thyroid cancer | Medullary thyroid cancer]] | *[[Thyroid cancer | Medullary thyroid cancer]] | ||
| + | *[[Non-small cell lung cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 34: | Line 35: | ||
[[Category:VEGF inhibitors]] | [[Category:VEGF inhibitors]] | ||
| + | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
Revision as of 01:45, 5 January 2018
General information
Class/mechanism: Tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor), VEGF (vascular endothelial cell growth factor), RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Vandetanib (Caprelsa) package insert PDF pages 6-8[5]
- Vandetanib (Caprelsa) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 4/6/2011: Initial FDA approval "for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease."
Also known as
- Code names: AZD6474, ZD6474
- Brand names: Caprelsa, Zactima
References
- ↑ 1.0 1.1 Vandetanib (Caprelsa) package insert
- ↑ Vandetanib (Caprelsa) package insert (locally hosted backup)
- ↑ Caprelsa manufacturer's website
- ↑ Caprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Vandetanib (Caprelsa) package insert PDF pages 6-8
- ↑ Vandetanib (Caprelsa) patient drug information (UpToDate)